454 related articles for article (PubMed ID: 19846915)
1. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
2. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma.
Yalcin M; Bharali DJ; Dyskin E; Dier E; Lansing L; Mousa SS; Davis FB; Davis PJ; Mousa SA
Thyroid; 2010 Mar; 20(3):281-6. PubMed ID: 20187783
[TBL] [Abstract][Full Text] [Related]
3. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
Mousa SA; Yalcin M; Bharali DJ; Meng R; Tang HY; Lin HY; Davis FB; Davis PJ
Lung Cancer; 2012 Apr; 76(1):39-45. PubMed ID: 22024450
[TBL] [Abstract][Full Text] [Related]
4. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.
Yalcin M; Dyskin E; Lansing L; Bharali DJ; Mousa SS; Bridoux A; Hercbergs AH; Lin HY; Davis FB; Glinsky GV; Glinskii A; Ma J; Davis PJ; Mousa SA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1972-80. PubMed ID: 20133461
[TBL] [Abstract][Full Text] [Related]
5. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
6. Identification and functions of the plasma membrane receptor for thyroid hormone analogues.
Lin HY; Cody V; Davis FB; Hercbergs AA; Luidens MK; Mousa SA; Davis PJ
Discov Med; 2011 Apr; 11(59):337-47. PubMed ID: 21524387
[TBL] [Abstract][Full Text] [Related]
7. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.
Davis PJ; Davis FB; Mousa SA; Luidens MK; Lin HY
Annu Rev Pharmacol Toxicol; 2011; 51():99-115. PubMed ID: 20868274
[TBL] [Abstract][Full Text] [Related]
8. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
Rebbaa A; Chu F; Davis FB; Davis PJ; Mousa SA
Angiogenesis; 2008; 11(3):269-76. PubMed ID: 18386142
[TBL] [Abstract][Full Text] [Related]
9. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.
Yalcin M; Lin HY; Sudha T; Bharali DJ; Meng R; Tang HY; Davis FB; Stain SC; Davis PJ; Mousa SA
Horm Cancer; 2013 Jun; 4(3):176-85. PubMed ID: 23456390
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
Schirner M; Hoffmann J; Menrad A; Schneider MR
Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594
[TBL] [Abstract][Full Text] [Related]
11. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.
Davis FB; Mousa SA; O'Connor L; Mohamed S; Lin HY; Cao HJ; Davis PJ
Circ Res; 2004 Jun; 94(11):1500-6. PubMed ID: 15117822
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of nongenomic actions of thyroid hormone.
Davis PJ; Leonard JL; Davis FB
Front Neuroendocrinol; 2008 May; 29(2):211-8. PubMed ID: 17983645
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.
Sudha T; Bharali DJ; Sell S; Darwish NHE; Davis PJ; Mousa SA
Horm Cancer; 2017 Jun; 8(3):157-165. PubMed ID: 28396979
[TBL] [Abstract][Full Text] [Related]
14. Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators.
Bridoux A; Cui H; Dyskin E; Yalcin M; Mousa SA
Bioorg Med Chem Lett; 2009 Jun; 19(12):3259-63. PubMed ID: 19427201
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
17. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model.
Mousa SA; Davis FB; Mohamed S; Davis PJ; Feng X
Int Angiol; 2006 Dec; 25(4):407-13. PubMed ID: 17164749
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone and angiogenesis.
Luidens MK; Mousa SA; Davis FB; Lin HY; Davis PJ
Vascul Pharmacol; 2010; 52(3-4):142-5. PubMed ID: 19879961
[TBL] [Abstract][Full Text] [Related]
19. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer.
Bharali DJ; Yalcin M; Davis PJ; Mousa SA
Nanomedicine (Lond); 2013 Dec; 8(12):1943-54. PubMed ID: 23448245
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer.
Rajabi M; Yalcin M; Mousa SA
Bioorg Med Chem Lett; 2018 Apr; 28(7):1223-1227. PubMed ID: 29519736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
